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ABSTRACT Telomerase is a ribonucleoprotein complex
that is thought to add telomeric repeats onto the ends of
chromosomes during the replicative phase of the cell cycle. We
tested this hypothesis by arresting human tumor cell lines at
different stages of the cell cycle. Induction of quiescence by
serum deprivation did not affect telomerase activity. Cells
arrested at the G1/S phase of the cell cycle showed similar
levels of telomerase to asynchronous cultures; progression
through the S phase was associated with increased telomerase
activity. The highest level of telomerase activity was detected
in S-phase cells. In contrast, cells arrested at G2/M phase of
the cell cycle were almost devoid oftelomerase activity. Diverse
cell cycle blockers, including transforming growth factor B31
and cytotoxic agents, also caused inhibition of telomerase
activity. These results establish a direct link between telom-
erase activity and progression through the cell cycle.
Telomeres form the ends of eukaryotic chromosomes consist-
ing of an array of tandem repeats of the hexanucleotide
5'-TTAGGG-3'. They are believed to protect the ends of
chromosomes against exonucleases and ligases, to prevent the
activation of DNA-damage checkpoints, and to counter the
loss of terminal DNA segments that occurs when linear DNA
is replicated (for reviews, see refs. 1-5). Telomerase, a ribo-
nucleoprotein enzyme, utilizes its own RNA as a template to
add the hexanucleotide to the ends of replicating chromosomes(2). Telomerase activity has been detected in the vast majority
of human tumors, but only in a few normal somatic cells(6-13). Differentiation of tumor cells is associated with a
pronounced downregulation of telomerase activity (13).
Neoplastic transformation is a concomitant of the accumu-
lation of multiple genetic changes that contribute to loss of
fidelity in the processes involved in replication, repair, and
segregation of the genome. In normal cells, fidelity is main-
tained by the coordinated activity of cyclin-dependent kinases,
cell-cycle checkpoint controls, and the repair pathway (for a
review, see ref. 14). The cell cycle involves coordination of a
variety of macromolecular syntheses, assemblies, and move-
ments. The progression of cells through the cell cycle is tightly
regulated by positive and negative signals (15). Progressive loss
of telomeres in normal cells is believed to activate sensing
mechanism(s) responsible for cellular senescence (1).
If telomerase adds TTAGGG repeats to replicating chro-
mosomes, it must be expressed at the S phase of the cell cycle.
We developed a simple nonradioactive method to quantify the
telomerase reaction products. By using this method, we exam-
ined the telomerase activity in human tumor cell lines by
synchronizing cells at different stages of the cell cycle and
demonstrate that the telomerase activity is regulated in a cell
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cycle-dependent manner. Withdrawal from the cell cycle did
not inhibit the telomerase activity. In contrast, as the cell
progresses through the cell cycle, maximum telomerase activ-
ity was detected in the S phase, with barely-detectable levels
observed at the G2/M phase.
MATERIALS AND METHODS
Cell Lines. The human cell lines used in the study, SW480
colon carcinoma cells, MDA435 breast carcinoma cells,
DU145 prostate carcinoma cells, MCF-7 breast carcinoma
cells, HOS-MNNG osteosarcoma cells, 293 immortal kidney
cells, and WI38 dermal fibroblasts, were obtained from the
American Type Culture Collection and maintained as recom-
mended by the American Type Culture Collection. Human
smooth muscle cells (early passage) were obtained from
Clonetics (San Diego).
Chemicals and Growth Factors. 5-Fluorouracil, methotrex-
ate, doxorubicin, nocodazole, thymidine, and aphidicolin were
from Sigma. Human transforming growth factor 31 (TGF-/1)
was from R & D Systems. PicoGreen was obtained from
Molecular Probes.
Telomerase Assay. Cells were treated with various agents for
the indicated length of time, and total cellular extracts were
made according to the protocol of Kim et al. (6) by using the
detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-
sulfonate (CHAPS). Freeze-thaw lysates in buffer B (see ref. 6)
minus CHAPS were made by dry-ice-ethanol and 37°C incuba-
tion for 3 cycles of 5 min each, followed by centrifugation at 12,000
x g for 15 min, and the supernatant was used to measure
telomerase activity. The PCR-based telomeric repeat amplifica-
tion protocol (TRAP) was used to determine telomerase activity
as described (13).A serial dilution (10-fold) of the protein extracts
from each cell line was made, and an appropriate range of protein
concentrations was selected that produced a linear response.
Telomerase reaction products were quantitated by using a
double-stranded DNA-specific fluorescent dye, PicoGreen, as
recommended by the manufacturer. Following the TRAP
assay without 32P-dNTP in triplicate, 45-,1l aliquots of TRAP
reaction products were transferred to 96-well plates and an
equal volume of diluted PicoGreen (1:200) was added. The
fluorescence was measured by using the Cytofluor Fluores-
cence Measurement System 2300 (Millipore). The excitation
wavelength was 485/20 nm and the emission intensity was
measured at 530/25 nm. The background fluorescence (from
extract-free TRAP assay) was subtracted from the sample
values. Routine controls for both qualitative and quantitative
Abbreviations: CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate; FACS, fluorescence-activated cell sorter; TRAP, te-
lomeric repeat amplification protocol; TGF-31, transforming growth
factor 31.
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FIG. 1. Exiting from cell cycle does not inhibit telomerase activity.(A) 293 cells were plated in growth medium in duplicate dishes, and
24 h later one set of dishes was washed free of medium and incubated
in basal medium minus serum for 72 h. Nuclear (Nuc) and cytoplasmic(Cyt) extracts were made from these cells, and increasing amounts of
extracts (0.01, 0.1, 1.0, and 3.0 jig of protein) were analyzed for
telomerase activity by TRAP assay. -TS, control for the TRAP assay
without the nontelomeric primer; +293, 1 jg of CHAPS extract from
293 cells as positive control for the TRAP assay; +RNase A, 293 cells
CHAPS extract pretreated with RNaseA (200 /Lg/ml) to inactivate the
RNA component of telomerase. (B) Photomicrograph of 293 cells
cultured in growth medium (+serum) and in basal medium minus
serum (-serum). (x24.6)
TRAP included (i) omitting nontelomeric primer, TS (6) and(ii) pretreatment of the protein extract with RNase A (200
gtg/ml). Each experiment was repeated two to four indepen-
dent times with cells at various passages.
Cell Cycle Analysis. Cell synchronization was achieved by
different agents. Quiescence was induced by serum deprivation
for 72 h as confirmed by thymidine incorporation. Cells were
synchronized at the Gi/S phase by sequential treatment with
5 mM thymidine for 20 h and 5 ,ug/ml aphidicolin for 16 h (16).
S-phase synchronization was achieved by treatment with hy-
droxyurea (0.3 mM) for 32 h. G2/M-phase synchronization was
obtained by treatment with 0.4 .ig/ml nocodazole for 16-20 h,
and nonadherent cells were analyzed (mitotic shakeup). The
percentage of the cells in different cell cycle phases was
determined by fluorescence-activated cell sorter (FACS) anal-
ysis of the DNA content as described (16, 17).
RESULTS
Withdrawal from Cell Cycle Does Not Affect Telomerase
Activity. 293 cells cultured in the presence or absence of serum
had similar telomerase activity in both the cytoplasm and the
nucleus (Fig. 1A), despite significant growth inhibition when
serum was withdrawn (Fig. 1B). The level of telomerase
activity in the serum-deprived culture did not change upon
restimulation with serum or cytokines such as interleukin la,
tumor necrosis factor a, and epidermal growth factor (not
shown). These agents, however, did induce transcription fac-
tors including nuclear factor-KB and Spl, demonstrating that
the serum-deprived cultures were capable of reentering the cell
cycle. Identical results were obtained with DU145 prostate
carcinoma, MDA435 breast carcinoma, and HOS-MNNG
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FIG. 2. Quantitation of telomerase reaction products. (A) Linearity of TRAP quantitation by PicoGreen assay. CHAPS extract from 293 cells(0-9 Lg of protein) were used in the TRAP assay, and the amplification products were quantified by PicoGreen. (B) Specificity of PicoGreen
quantitation assay. CHAPS extracts (1 .cg) from 293 cells (telomerase positive), smooth muscle cells, and WI38 fibroblasts (both telomerase
negative) were analyzed by TRAP assay for telomerase activity, and the products were analyzed by PicoGreen assay. -Ext, minus extract control;
+293 Ext, positive control; +RNase A, extract pretreated with RNase A; -TS, minus nontelomeric primer TS; SMC, WI38, extracts from smooth
muscle cells (early passage) and WI38 fibroblasts. (C) A simple method to isolate telomerase activity. Extracts from 293 cells, SW480 cells, ana
HOS-MNNG cells were made following the CHAPS protocol (6) or by freeze-thaw cycle (F.T., as indicated in Materials and Methods) and equal
amounts of protein (0.5 ,ug) were analyzed simultaneously by TRAP-PicoGreen assay for telomerase activity. (D) Quantitation of telomerase
activity in nuclear and cytoplasmic extracts of 293 cells. Extracts from Fig. 1 were analyzed by TRAP-PicoGreen assay.
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osteosarcoma tumor cells (not shown). These results indicate
that quiescent tumor cells do retain telomerase activity.Quantitation of Telomerase Activity. The currently used
TRAP assay to measure telomerase activity is essentially a
qualitative assay, and only extreme differences in the telom-
erase levels are interpretable. Hence, we next developed a
simple method to quantify the telomerase reaction products by
using a double-stranded DNA-specific fluorescent dye, Pico-
Green (Fig. 2). The intensity of fluorescence was linear with
reference to the protein concentration (0-1 jig), reaching
saturation at concentrations greater than 1 mg (Fig. 2A). The
specificity of this assay is shown in Fig. 2B; the fluorescent
intensity was negligible in samples (i) without the protein
extract, (ii) with RNase A pretreatment, (iii) without nonte-
lomeric primer TS, and (iv) telomerase-negative cells (includ-
ing early passage human smooth muscle cells and WI38 human
fibroblasts). The fluorescent intensity of the reaction products
was linear with reference to the amount of the products and
was abolished by DNase treatment of the TRAP reaction
products (not shown). Comparison of CHAPS extract with a
simple freeze-thaw extract (see Materials and Methods) by
quantitation showed 2- to 8-fold increase in the telomerase
activity in diverse tumor cell lines (Fig. 2C).
Application of this assay for quantitative measurement of
the telomerase activity in extracts of serum-deprived 293 cells(Fig. 2D) showed similar levels in the nucleus of the serum-
deprived cultures; in proliferating cells (plus serum), slightly
elevated nuclear telomerase activity was detected with a
corresponding decrease in the cytoplasmic telomerase activity.
These results confirmed that when analyzed in tandem, the
qualitative and quantitative TRAP assays are complementary.
Hence, we used this method to quantify the telomerase activity
in subsequent experiments.
Telomerase Activity Is Cell-Cycle Regulated. Although
withdrawal from the cell cycle by serum deprivation did not
appreciably alter the relative telomerase levels in tumor cells,
telomerase activity may fluctuate at distinct stages of the cell
cycle. SW480 colon carcinoma cells were arrested at the Gi/S,
S, or G2/M phase by thymidine/aphidicolin, hydroxyurea, or
nocodazole treatment, respectively, as indicated in Materials
and Methods. After cells were released from the block by
washing them free of the agents (0 time) and replating for 12
and 24 h, telomerase activity was measured (Fig. 3). Cells
arrested at the Gi/S phase had similar telomerase activity to
the asynchronous cells. Upon reentry into the cell cycle, these
cells showed a gradual increase in telomerase activity (Fig. 3
A and B). The FACS profile of the SW480 cells arrested at
different stages of the cell cycle followed by 24-h release is
shown in Fig. 3C. Cells arrested at the S phase had the highest
level of telomerase activity; upon progression through the cell
cycle, they showed a gradual decrease in telomerase activity.
Strikingly, cells arrested at the G2/M phase showed almost
no telomerase activity. The inhibition was maintained for 12 h
following release from the G2/M block. At 24 h, telomerase
levels were similar to those of cells arrested at the S phase.
Nocodazole (0.4 mg/ml) did not directly inhibit the telomerase
activity in vitro, suggesting that the decline of telomerase
activity in the G2/M blocked cells must be cell mediated. An
almost complete lack of telomerase activity in G2/M-
synchronized cells was seen in two other tumor cell lines,
MCF-7 and MDA435 (breast carcinoma cells; not shown).
Mixing of extracts from G2/M-arrested SW480 cells with
extracts from asynchronous cells did not affect telomerase
activity. This suggests that no inhibitor was present in the
extracts of cells synchronized at G2/M.
Effect of TGF-81 and Cytotoxics on Telomerase Activity.
TGF-31, a growth inhibitory polypeptide, arrests the cell cycle
in susceptible cells in middle to late G1 phase (18). We tested
whether the growth arrest mediated by TGF-,31 is reflected in
telomerase inhibition. MDA435 breast carcinoma cells were
treated with TGF-31 for 1 week and telomerase activity was
measured (Fig. 4 A and B). Growth inhibition by TGF-f31 in
these cells was accompanied by a marked reduction in telom-
erase activity. We next tested the effects of cytotoxic agents
including methotrexate and 5-fluorouracil, which block cells at
the S phase (19), and doxorubicin, which blocks cells predom-
inantly at the G2/M phase (20). SW480 colon carcinoma cells
were treated for 72 h with these agents, and telomerase activity
was measured (see Fig. 4 C and D). Treatment with doxoru-
bicin abolished the telomerase activity, similar to the nocoda-
zole treatment in the nonadherent cells. Treatment with
methotrexate and 5-fluorouracil caused a marked reduction of
telomerase activity despite lack of toxicity at 72 h. None of
these agents directly inhibited the telomerase activity in vitro,
suggesting that the inhibition must be cell mediated.
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FIG. 3. Cell-cycle regulation of telomerase activity. Freeze-thaw
extracts of SW-480 colon carcinoma cells asynchronized (Async) or
blocked at Gi/S (thymidine/aphidicolin), G2/M (nocodazole), or S
phase (hydroxyurea) followed by release for 12 and 24 h as described,
were analyzed for telomerase activity by TRAP assay (A) and TRAP-
PicoGreen quantitation (B). InA, 0.1 and 1.0 /Lg of protein was used.
In B, 0.2 tzg of protein was used. (C) FACS profile of asynchronized(Async), synchronized (0 time), and 24-h released (Rel) cultures are
shown. Cell-cycle distribution at 0 time: G1/S block, 34% Go/Gi, 64%
S, and 2% G2/M; S block, 27% Go/Gi, 47% S, and 23% G2/M; and
G2/M block, 1% Go/Gi, 4% S, and 90% G2/M. In comparison, the
distribution of asynchronized cultures was 63% Go/Gi, 28% S, and
10% G2/M.
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FIG. 4. Effect of antiproliferative agents on telomerase activity in tumor cells. (A) MDA-435 breast carcinoma cells were treated with or without
TGF-/31 (10 pM) for 1 week and the freeze-thaw lysates were analyzed for telomerase activity. Photomicrograph of the cells prior to analysis. (x30.).(B) Telomerase activity from A was quantified by TRAP-PicoGreen assay using 0.5 gg of protein. (C) SW480 colon carcinoma cells were treated
with vehicle (0.1% dimethyl sulfoxide, control), 10 tLM doxorubicin (DOX), 10 ,LM 5-fluorouracil (FU), or 10 ,tM methotrexate (MTX) for 72 h.
Freeze-thaw lysates were analyzed for telomerase activity by TRAP assay using 0.05, 0.2, and 1.0 ,tg of protein. -TS and +RNase A lanes are as
described in Fig. 1. (D) Samples from C were quantified by TRAP-PicoGreen assay for telomerase activity using 0.5 g,g of protein.
DISCUSSION
The present study demonstrates that in tumor cell lines,
telomerase activity changes as cells progress through the cell
cycle. Withdrawal from the cell cycle by serum deprivation did
not cause a reduction of telomerase activity. Thus quiescent
cells do retain telomerase activity, a finding that is consistent
with the recent detection of telomerase activity in noncycling
hematopoietic cells, including leukocytes from peripheral
blood, cord blood, and bone marrow (9) and resting T and B
lymphocytes (7).
In the Xenopus model, telomerase activity was detected in
M-phase extracts (21); it has been suggested that in this model
either telomerase is not cell-cycle regulated or, alternatively,
that the early embryonic stages of development have active
telomerase that is undetectable at later stages. The latter
possibility is supported by our recent findings that in diverse
immortal cells, differentiation in vitro was associated with a
pronounced downregulation of telomerase activity (13). It is
likely that the mechanism(s) regulating telomerase activity in
Xenopus is different from that of human tumor cells.
If telomerase is required for the maintenance of telomeres,
it must be active during the DNA replication stage (S phase)
but not necessarily in the nonreplicative phase of the cell
cycle-for example, the G2/M phase. The present results are
consistent with this prediction (see Fig. 5). As cells progress
through the Gi/S phase of the cell cycle, telomerase activity
gradually increases. The highest level of telomerase activity is
present at the replicative S phase, with a virtual loss of activity
at the G2/M phase. However, withdrawal from the cell cycle
did not cause a reduction of telomerase activity, and reentry
of quiescent cells into the cell cycle mediated by cytokines and
growth factors did not cause any further increase in telomerase
activity. These latter results suggest that immediate early genes
that are induced by these stimuli are unlikely to play a
regulatory role in modulating telomerase activity.
The lack of telomerase activity in tumor cells synchronized
at the G2/M phase is striking. Two different G2/M blockers
(nocodazole and doxorubicin) caused a complete abolition of
telomerase activity. Although mixing experiments with G2/M
extracts did not reveal the presence of an inhibitory mole-
cule(s), it is tempting to speculate that one or several proteins
that are expressed and/or activated during the G2/M phase
may inhibit telomerase activity. Telomerase activity was in-
hibited by TGF-131, a Gi/S blocker (18), in comparison to the
thymidine/aphidicolin-mediated Gi/S block, which showed no
effect. Similarly, methotrexate- and 5-fluorouracil-mediated
S-phase block (22) caused inhibition of telomerase activity,
FIG. 5. Proposed model for cell-cycle regulation of telomerase
activity.
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whereas a hydroxyurea-mediated S-phase block did not. These
results suggest that inhibition of telomerase activity by these
agents is complex and may be indirect.
We have recently demonstrated that induction of differen-
tiation in HL-60 cells by diverse agents results in a pronounced
downregulation of telomerase activity (13). These inducers
arrested the HL-60 cells at the GI phase of the cell cycle.
Interestingly, when asynchronous HL-60 cells were enriched
for G1, S, and G2/M phase cells by centrifugal elutriation (23)
and analyzed for telomerase activity, no differences were seen(data not shown). This suggests that measurement of telom-
erase activity at distinct stages of the cell cycle may be affected
by the mode of enrichment-i.e., native cells versus the use of
chemical blockers. Alternatively, telomerase activity in leuke-
mic cells is not cell cycle-dependent. This latter possibility is
supported by the recent detection of telomerase activity in
diverse normal hematopoietic cells (7, 9). Clarification of this
awaits the molecular cloning of telomerase subunits.
Several reports have documented a functional relationship
between telomerase and the cell cycle. In the ciliate Tetrahy-
mena, alteration of a single nucleotide in the T4G2 telomeric
repeat sequence disrupts cell division and causes cellular
senescence (24). In Saccharomyces cerevisiae, telomeric DNA
is replicated in the late S phase (25), and loss of a single
telomere results in cell cycle arrest at G2 (26). It has been
postulated that telomere replication may serve as a checkpoint
for completion of the S phase (3). In the macronucleus of the
ciliate Oxytricha nova, the telomeres are bound to a het-
erodimeric telomere protein that is phosphorylated by cyclin-
dependent kinases (27). In Xenopus extracts, one of the
subunits is phosphorylated during the M phase and dephos-
phorylated at interphase (27). Telomeres are likely to play a
role in nuclear architecture by localizing chromosomes to the
nuclear envelope (28, 29) or to the nuclear matrix (30).
Progression through the M phase involves phosphorylation of
a set of proteins including histone H1, nuclear lamins, vimen-
tin, and caldesmon. The Cdc2/cyclin A and Cdc2/cyclin B
kinases are required for most of these events (for a review, see
ref. 15). Thus, our results of cell cycle-dependent regulation of
telomerase activity are consistent with the hypothesis that
telomeric DNA synthesis, telomere structure, and telomerase
function are subject to cell-cycle regulation.
Telomerase inhibitors may merit a place in cancer thera-
peutics (for reviews, see refs. 4, 5, and 31). Understanding the
regulation of telomerase activity in tumor cells is pivotal to
validating its therapeutic relevance in cancer. To date, no
regulators of telomerase activity have been described, with the
exception of downregulation of telomerase activity observed in
differentiating tumor cells in vitro (13). Our present findings of
cell cycle-dependent regulation of telomerase activity, and
particularly the virtual abolition of telomerase activity in
G2/M-arrested tumor cells, provide a valuable clue to the
regulation of telomerase in tumor cells.
Note Added in Proof. At press time, a concurrent report (32) showed
telomerase activity to be constant at all stages of the cell cycle in
elutriated cells, consistent with our HL-60 results. Holt et al.'s studies
were done using a different inducer of quiescence and different means
of cell-cycle arrest (elutriation), which suggests that analysis of telom-
erase activity depends upon the nature of cell-cycle perturbation.
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